ASCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order of components, figure ...

Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma Anti–vascular endothelial growth factor therapy enhances PD-1 ...

Circulating tumor DNA (ctDNA) assays are promising tools for the prediction of cancer treatment response. Here, we build a framework for the design of ctDNA biomarkers of therapy response that ...

Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma: Immune-Förster Resonance Energy Transfer and the Dynamic Tumor Immune Microenvironment This retrospective ...

The use of electronic patient-reported outcome measures (ePROMs) in supportive cancer care can lead to benefits, such as identifying at-risk patients in need of closer monitoring and treatment.

What's in the Syringe—Or Isn't: Defining Perioperative Supportive Care Interventions for Improved Surgical Outcomes Among Older Adults With Cancer The thoughtful manuscript published by Liao et al 1 ...

In the article that accompanies this editorial by Lam et al, 6 the authors systematically reviewed randomized controlled trials (RCTs) of supportive care interventions for older adults with cancer ...

Of 922 screened titles, Lam et al 7 identified only 11 studies that met the inclusion criteria of randomized controlled trials of nonpharmacologic, noninterventional supportive care interventions ...

Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in ...

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group Treatment stratification in ALL ...